about
Oxidative stress and endothelium influenced by metformin in type 2 diabetes mellitus.2,3,7,8-TCDD exposure, endothelial dysfunction and impaired microvascular reactivity.Evaluation of skin microcirculation during hemodialysis.Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines updatePlacental growth factor, pregnancy-associated plasma protein-A, soluble receptor for advanced glycation end products, extracellular newly identified receptor for receptor for advanced glycation end products binding protein and high mobility group boPathobiochemistry of nephrotic syndrome.Relationship between advanced glycoxidation end products, inflammatory markers/acute-phase reactants, and some autoantibodies in chronic hemodialysis patients.Advanced glycation end products in clinical nephrology.Vitamin D Binding Protein Is Not Involved in Vitamin D Deficiency in Patients with Chronic Kidney Disease.Advanced glycoxidation end products in chronic diseases-clinical chemistry and genetic background.Oxidative stress and signal transduction pathways in alcoholic liver disease.Matrix metalloproteinases in serum and the follicular fluid of women treated by in vitro fertilization.Placental growth factor may predict increased left ventricular mass index in patients with mild to moderate chronic kidney disease--a prospective observational study.Pregnancy-associated plasma protein A: spotlight on kidney diseases.Pregnancy-associated plasma protein A (PAPP-A) and preeclampsia.HMGB1, S100 proteins and other RAGE ligands in cancer - markers, mediators and putative therapeutic targets.Pregnancy-Associated Plasma Protein A2 in Hemodialysis Patients: Significance for Prognosis.Polymorphisms of the receptor for advanced glycation end products and glyoxalase I and long-term outcome in patients with breast cancer.Diagnostic Importance of Selected Protein Serum Markers in the Primary Diagnostics of Prostate Cancer.Skin autofluorescence relates to soluble receptor for advanced glycation end-products and albuminuria in diabetes mellitus.Pregnancy-associated plasma protein A associates with cardiovascular events in diabetic hemodialysis patients.Anti-inflammatory properties of high-density lipoprotein cholesterol in chronic hemodialysis patients: impact of intervention.Lower retinol levels as an independent predictor of mortality in long-term hemodialysis patients: a prospective observational cohort study.Soluble receptor for advanced glycation end-products (sRAGE) and polymorphisms of RAGE and glyoxalase I genes in patients with pancreas cancer.Biochemical oxidative stress-related markers in patients with obstructive sleep apnea.Correlation of Vitreous Vascular Endothelial Growth Factor and Uric Acid Concentration Using Optical Coherence Tomography in Diabetic Macular Edema.Genetic predisposition to advanced glycation end products toxicity is related to prognosis of chronic hemodialysis patients.Soluble receptor for advanced glycation end products in physiological and pathological pregnancy.Fibroblast growth factor 23 and matrix-metalloproteinases in patients with chronic kidney disease: are they associated with cardiovascular disease?Advanced glycation end products in hemodialyzed patients with diabetes mellitus correlate with leptin and leptin/body fat ratio.Glycoxidation and inflammation in chronic haemodialysis patients.Relationship of pregnancy-associated plasma protein-a to renal function and dialysis modalities.Advanced glycation end-products in patients with chronic alcohol misuse.Intravenous iron gluconate administration increases circulating PAPP-A in hemodialysis patients.Fetuin-A early after renal transplantation.Glyoxalase I Glu111Ala polymorphism in patients with breast cancer.Influence of parenteral iron therapy and oral vitamin E supplementation on neutrophil respiratory burst in chronic hemodialysis patients.A419C (E111A) polymorphism of the glyoxalase I gene and vascular complications in chronic hemodialysis patients.Soluble receptor for advanced glycation end products in patients with decreased renal function.Placental Growth Factor in Bladder Cancer Compared to the Diagnostic Accuracy and Prognostic Performance of Vascular Endothelial Growth Factor A.
P50
Q33299232-CB7E602E-B9BB-40A9-9C2C-B45FFB74230CQ33305054-D7556775-8A04-4395-9E40-39447A65996DQ33527533-13D47CF1-7C9A-45C6-B116-4E375414EA1CQ34441837-0B5A9D03-6C8A-465E-8D7C-1EAD59474C56Q34493096-DE3766FF-F5AF-47D4-B56B-054372B81434Q35079070-F14A15D3-91A4-4DB0-BF2D-60BF95074B5CQ35106734-9C9F42B9-CBA7-4082-8297-150F3791C3B5Q35609319-DC05193C-23E4-42BB-B31E-B217FDCC6C56Q35614174-399C8C6F-63C5-476F-9080-9724A6E2623FQ36220722-E4BDCACF-17F2-4519-B5F0-1A1154F739DAQ36339561-BB9C62B4-8A3B-4E48-A04B-E0C19AB76647Q36434720-80F044FA-ADD4-4BA7-AE40-BC001C2EC803Q37113344-ECE85767-A84D-4A37-B48E-36AB8B6452C8Q38031040-77392770-5911-4784-BDA3-19C189EE45A4Q38208332-A016E876-945A-45B6-8F01-3085D0483DF2Q38723623-07641DC2-7CFD-4A85-862A-4FFCC4DB596AQ40074539-C90679C3-5635-433A-8B03-489D8269EF6BQ40127796-B9799E58-9974-4E61-BA1F-F356969B5DB9Q40295076-97BCD935-627C-4675-B8BD-9761D8417E29Q40509446-5A68F1E9-CC47-4322-A4CA-983E82200BA0Q42202543-C89871E6-A870-4887-B05C-EECA02F87444Q42910307-672FFEF9-538E-4984-8B6D-03070D834723Q43028853-29BAE122-89D4-4EA7-A18F-2F1C07EDC77FQ43096148-AE690E73-4ED1-4D7F-B4B2-36A43F01B884Q43103931-0377A235-6CD2-452E-B6C9-FB777F3373BAQ43148680-CCBD568E-65A2-4716-8463-B28B2501B04BQ43148971-481021DB-3A74-4771-ACDA-998ABC471F59Q43243422-C648E377-3E22-46EE-BD82-32B1BCE63A71Q43268301-F70D4C71-607F-49BB-9899-AC528CC5A12FQ44435947-D5498F96-EE69-4F04-A783-95E6562B7E9AQ44647149-385274C9-4D8F-476A-B1FD-A6FC47C7642FQ44739342-319AC7C8-2F7B-4B1A-B267-9BF0F90A3E80Q44945332-FDDA6B8A-B65D-40EE-852D-15A29C82CB98Q45250531-9E571A4C-454E-4616-AA1A-BC054CF0B753Q45923666-7D3B514F-B6CE-4E2F-BB27-A22492A62378Q46006352-126AEB61-98C5-4AD3-9707-E609AE1D6F67Q46418925-236A603B-0CE8-4953-8ED1-046E7D32DBA5Q46850785-F8FDC499-5038-4400-B31D-F18439E53D56Q46954195-3CB7C408-9358-4915-B278-B6088E9CD8C5Q47255039-8031F761-0EF1-4664-BC1D-9EAFB3D19CED
P50
description
hulumtuese
@sq
researcher
@en
ricercatrice
@it
wetenschapper
@nl
հետազոտող
@hy
name
Marta Kalousova
@ast
Marta Kalousova
@en
Marta Kalousova
@es
Marta Kalousova
@nl
Marta Kalousova
@sl
Marta Kalousová
@cs
type
label
Marta Kalousova
@ast
Marta Kalousova
@en
Marta Kalousova
@es
Marta Kalousova
@nl
Marta Kalousova
@sl
Marta Kalousová
@cs
altLabel
Janebova M
@en
Janebova Marta
@en
Janebová M
@en
Janebová Marta
@en
Kalousova M
@en
Kalousová M
@en
Kalousová Marta
@en
prefLabel
Marta Kalousova
@ast
Marta Kalousova
@en
Marta Kalousova
@es
Marta Kalousova
@nl
Marta Kalousova
@sl
Marta Kalousová
@cs
P214
P1053
D-1530-2017
P106
P1153
7004217459
P19
P21
P214
P31
P3829
P496
0000-0001-5928-3074
P569
1974-01-01T00:00:00Z
P691
mzk2005318016
P735
P7859
viaf-84649661